Fewer than one in 10 patients who could benefit from obesity jabs like Wegovy are able to get them, caution the World Health Organization as it issues its first recommendations on the therapies.
With more than one billion individuals worldwide now obese, it is advocating for increased and just access to GLP-1 medication.
Based on estimates, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"Our latest guidelines acknowledges that obesity is a chronic disease that can be addressed with holistic and ongoing treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant obstacles to widespread availability to the injections that can aid individuals in losing considerable body mass, explains the body.
Weight-Loss Drug Shortage
Even in the present best projected outlook, the manufacturing of these medications might only reach about 100 million people – less than 10% of those who need them, as stated by the WHO.
The advice encourages countries and companies to increase access, via approaches such as patent sharing.
The intellectual property rights on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026.
The Way Obesity Injections Function
These medications replicate a natural hormone to slow digestion, reduce hunger and increase satiety so individuals consume fewer calories.
People typically begin shedding pounds in the initial weeks of starting on the once-weekly jabs.
Studies indicates patients may regain a significant portion within a year of discontinuing the drug, when their typical appetite come back.
To be overweight or obese elevates your chance for experiencing diseases, including type 2 diabetes, heart disease, brain attack, and some malignancies.
Excess weight affects individuals in countries worldwide and was linked to millions of deaths worldwide in 2024, as per the health agency.
